Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

182 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network.
Terpos E, Sezer O, Croucher PI, García-Sanz R, Boccadoro M, San Miguel J, Ashcroft J, Bladé J, Cavo M, Delforge M, Dimopoulos MA, Facon T, Macro M, Waage A, Sonneveld P; European Myeloma Network. Terpos E, et al. Among authors: croucher pi. Ann Oncol. 2009 Aug;20(8):1303-17. doi: 10.1093/annonc/mdn796. Epub 2009 May 22. Ann Oncol. 2009. PMID: 19465418 Free article. Review.
Myeloma bone disease and proteasome inhibition therapies.
Terpos E, Sezer O, Croucher P, Dimopoulos MA. Terpos E, et al. Blood. 2007 Aug 15;110(4):1098-104. doi: 10.1182/blood-2007-03-067710. Epub 2007 May 9. Blood. 2007. PMID: 17494860 Free article. Review.
The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis.
Terpos E, Kastritis E, Roussou M, Heath D, Christoulas D, Anagnostopoulos N, Eleftherakis-Papaiakovou E, Tsionos K, Croucher P, Dimopoulos MA. Terpos E, et al. Leukemia. 2008 Dec;22(12):2247-56. doi: 10.1038/leu.2008.235. Epub 2008 Sep 4. Leukemia. 2008. PMID: 18769451 Clinical Trial.
Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma.
Terpos E, Heath DJ, Rahemtulla A, Zervas K, Chantry A, Anagnostopoulos A, Pouli A, Katodritou E, Verrou E, Vervessou EC, Dimopoulos MA, Croucher PI. Terpos E, et al. Among authors: croucher pi. Br J Haematol. 2006 Dec;135(5):688-92. doi: 10.1111/j.1365-2141.2006.06356.x. Br J Haematol. 2006. PMID: 17107351 Free article.
Anti-tumour activity of bisphosphonates in human myeloma cells.
Shipman CM, Rogers MJ, Apperley JF, Graham R, Russell G, Croucher PI. Shipman CM, et al. Among authors: croucher pi. Leuk Lymphoma. 1998 Dec;32(1-2):129-38. doi: 10.3109/10428199809059253. Leuk Lymphoma. 1998. PMID: 10037008 Review.
Bisphosphonates in multiple myeloma.
Apperley JF, Croucher PI. Apperley JF, et al. Among authors: croucher pi. Pathol Biol (Paris). 1999 Feb;47(2):178-81. Pathol Biol (Paris). 1999. PMID: 10192885 Review.
182 results